Compare ASTC & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTC | LEXX |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5M | 9.5M |
| IPO Year | 2020 | 2011 |
| Metric | ASTC | LEXX |
|---|---|---|
| Price | $3.50 | $4.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.3K | ★ 20.6K |
| Earning Date | 11-13-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2600.00 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,000,000.00 | $705,923.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6,915.00 |
| P/E Ratio | $14.32 | ★ N/A |
| Revenue Growth | N/A | ★ 52.05 |
| 52 Week Low | $1.92 | $0.35 |
| 52 Week High | $68.85 | $21.60 |
| Indicator | ASTC | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 26.15 | 54.77 |
| Support Level | $2.14 | $2.67 |
| Resistance Level | $3.76 | $4.79 |
| Average True Range (ATR) | 0.34 | 0.39 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 7.01 | 56.88 |
Astrotech Corp is a science and technology company. It creates, operates and scales businesses through its subsidiaries and technology platforms, including space-related technology, instrumentation, mass spectrometry, gas chromatography, process-control and environmental analysis technologies. It is evaluating opportunities to identify, develop and commercialize technologies with potential applications in space, defense, industrial, environmental, quantum computing, AI, semiconductor materials, lunar infrastructure and related markets. Its products include Tracer 1000 ETD, tracer 1000 NTD, Labrador HHGC, Fenceline GC, AgLab 1000-D2, among others. It operates in single segment.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.